Cargando…

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial

BACKGROUND AND OBJECTIVE: Cognitive impairments associated with schizophrenia (CIAS) predict poor functional outcomes, but there are currently no approved pharmacological treatments for patients with CIAS. Additional cognitive stimulation may be required for pro-cognitive medications to improve effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harvey, Philip D., Bowie, Christopher R., McDonald, Sean, Podhorna, Jana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105423/ https://www.ncbi.nlm.nih.gov/pubmed/32036587 http://dx.doi.org/10.1007/s40261-020-00893-8

Ejemplares similares

S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL
por: Hake, Sanjay, et al.
Publicado: (2020)

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
por: Rosenbrock, Holger, et al.
Publicado: (2023)

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021)

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)

Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme
por: Falkai, P., et al.
Publicado: (2023)

Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)
por: Schultheis, Christian, et al.
Publicado: (2022)

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
por: Rosenbrock, Holger, et al.
Publicado: (2018)

Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial
por: Wunderlich, Glen, et al.
Publicado: (2023)

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
por: Moschetti, Viktoria, et al.
Publicado: (2018)

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor
por: Desch, Michael, et al.
Publicado: (2021)

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study
por: Moschetti, Viktoria, et al.
Publicado: (2017)

The relationship between cognition and functioning in schizophrenia: A semi-systematic review
por: Kharawala, Saifuddin, et al.
Publicado: (2021)

Pharmacotherapy for treatment-resistant schizophrenia
por: Mcilwain, Meghan E, et al.
Publicado: (2011)

Pharmacotherapy of Schizophrenia in Acute and Maintenance Phase
por: KIRLI, Umut, et al.
Publicado: (2021)

Adjunctive antidepressive pharmacotherapy in schizophrenia patients
por: Zink, M.
Publicado: (2021)

Validation of a computerized decision support system to review pharmacotherapy treatment: scheduling guidelines
por: Zapelini, Clávison Martinelli, et al.
Publicado: (2022)

Approaches to improve adherence to pharmacotherapy in patients with schizophrenia
por: Shuler, Kimberly M
Publicado: (2014)

Review of pharmacotherapy for smoking cessation in patients with schizophrenia
por: Shawen, Avery E., et al.
Publicado: (2018)

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study
por: Desch, Michael, et al.
Publicado: (2023)

Falls in nursing home residents receiving pharmacotherapy for anemia
por: Reardon, Gregory, et al.
Publicado: (2012)

In silico hippocampal modeling for multi-target pharmacotherapy in schizophrenia
por: Sherif, Mohamed A., et al.
Publicado: (2020)

Cognitive deficits and functional outcome in schizophrenia
por: Bowie, Christopher R, et al.
Publicado: (2006)

Feasibility and Validity of Computerized Ecological Momentary Assessment in Schizophrenia
por: Granholm, Eric, et al.
Publicado: (2008)

A Computerized Bioinspired Methodology for Lightweight and Reliable Neural Telemetry
por: Adeluyi, Olufemi, et al.
Publicado: (2020)

Merging the Pathophysiology and Pharmacotherapy of Tics
por: Augustine, Farhan, et al.
Publicado: (2019)

Two-stage CNNs for computerized BI-RADS categorization in breast ultrasound images
por: Huang, Yunzhi, et al.
Publicado: (2019)

The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction
por: Falkai, P., et al.
Publicado: (2011)

The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
por: Cotter, Jack, et al.
Publicado: (2019)

Evaluation of cancer prevention strategies by computerized simulation model: methodological issues.
por: Yamaguchi, N, et al.
Publicado: (1994)

Factors Affecting Medication Adherence in Children Receiving Outpatient Pharmacotherapy and Parental Adherence
por: Nagae, Masaharu, et al.
Publicado: (2015)

Multiple serum biomarkers for predicting suicidal behaviours in depressive patients receiving pharmacotherapy
por: Kim, Jae-Min, et al.
Publicado: (2023)

Computerized text and voice analysis of patients with chronic schizophrenia in art therapy
por: Sprotte, Yvonne
Publicado: (2023)

Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
por: Behrouzian, Forouzan, et al.
Publicado: (2022)

Assessing Patient Attitudes to Computerized Screening in Primary Care: Psychometric Properties of the Computerized Lifestyle Assessment Scale
por: Ahmad, Farah, et al.
Publicado: (2008)

Alzheimer’s Treatment: Real-World Physician Behavior Across Countries
por: Podhorna, Jana, et al.
Publicado: (2020)

Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment
por: Edelsohn, Gail A., et al.
Publicado: (2021)

Prediction of Suicidality According to Serum Folate Levels in Depressive Patients Receiving Stepwise Pharmacotherapy
por: Kim, Jae-Min, et al.
Publicado: (2021)

The pharmacotherapy of infections in patients with mental disorders receiving psychotropic drugs: Focus on good practices
por: Stuhec, M.
Publicado: (2021)

Effectiveness of Internet-Delivered Computerized Cognitive Behavioral Therapy for Patients With Insomnia Who Remain Symptomatic Following Pharmacotherapy: Randomized Controlled Exploratory Trial
por: Sato, Daisuke, et al.
Publicado: (2019)

New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
por: Jeon, Won Je, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f94v8licki5j1vn15rah2m3tos